BAP1 and pleural mesothelioma: In a completed clinical trial (NCT02860286 - ClinicalTrials.gov, 2021) involving 74 patients with relapsed or refractory BRCA1-Associated Protein 1 (BAP1)-inactivated pleural mesothelioma, Tazemetostat showed limited efficacy: only two patients had partial responses, and none achieved a complete response (Zauderer et al., 2022).